GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Taigen Biopharmaceuticals Holdings 4157.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

8.13

+4.10%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Taigen Biopharmaceuticals Holdings

Its shares trade on Taipei Exchange under the ticker 4157.TWO. It has been listed since 30 August 2013. In the fiscal year to 31 December 2025, it reported revenue of TWD 259.5m and net income of TWD 45.2m. At that date it held total assets of TWD 1.17bn and shareholders' equity of TWD 1.07bn.

TaiGen Biopharmaceuticals Holdings Ltd. engages in the development of novel therapeutics for infectious diseases, cancer, and diabetes-related complications. The company is headquartered in Taipei City, Taipei. The company went IPO on 2013-08-30. The firm's products mainly are new chemical entities (NCEs) in infectious diseases, cancer and diabetes-related complications. Its products include Nemonoxacin, Burlxafor and TG-2349. The firm receives its revenue mainly from the authorization of Nemonoxacin products.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
30 Aug 2013

Leadership

Pay as last reported

  • Mr. Kuo-Lung HuangChairman of the Board, since 2018TWD 15,000
  • Ms. Li-Wen ChangGeneral Manager
  • Mr. Richard LuDeputy General Manager-Finance and Administration Division, Corporate Governance Officer
  • Mr. Cheng-Yuan TsaiDeputy General Manager-Preclinical Research Division
  • Mr. Mark KaoHead of Accounting
  • Mr. Hong-Jen ChangDirectorTWD 135,000
  • Mr. I-Jen HuangDirectorTWD 132,000
  • Mr. Weng-Foung HuangDirectorTWD 1.1m
  • Mr. Peter WuDirectorTWD 135,000
  • Xunyuan ZouDirector
  • Yiqun HuangIndependent Director
  • Meili SuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Develops novel therapeutics for infectious diseases, cancer, and diabetes-related complications.
  • Headquartered in Taipei City, Taipei.
  • Products include Nemonoxacin, Burlxafor, and TG-2349.

Weaknesses

  • Revenue mainly from authorization of Nemonoxacin products.
  • Relies on a single product for primary revenue generation.
  • No information provided on product pipeline beyond current offerings.

Opportunities

  • Expansion into new therapeutic areas within health care sector.
  • Potential for additional product approvals and market entry.
  • Growth in biotechnology industry could increase market opportunities.

Threats

  • Dependence on Nemonoxacin for revenue may pose financial risk.
  • Competition in biotechnology sector could impact market share.
  • Regulatory challenges may affect product approvals and revenue streams.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.